Relay Therapeutics (RLAY) Stock Price

Relay Therapeutics Price

NASDAQ·CLOSED
19.77USD+0.02 (+0.10 %)
Market closed

Revenue at Relay Therapeutics has contracted by 28.6% per year over the past 5 years to 15.36 M USD. Relay Therapeutics's net margin stands at -1,800.6%, up from -12,012.9% several years earlier. Analysts set a median price target of 14.28 USD, implying 27.8% below the current price. Of 18 analysts, 17 rate the stock a buy — an overall Buy consensus. The stock trades about 508% above its 52-week low.

Relay Therapeutics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Relay Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Relay Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Relay Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Relay Therapeutics Stock Price History
DateRelay Therapeutics Price
8/7/202619.77 USD
8/6/202619.75 USD
8/5/202619.40 USD
8/4/202619.55 USD
8/3/202618.78 USD
7/31/202618.83 USD
7/30/202619.45 USD
7/29/202618.16 USD
7/27/202618.76 USD
7/23/202619.09 USD
7/22/202619.27 USD
7/21/202619.30 USD
7/20/202619.18 USD
7/17/202619.91 USD
7/16/202619.37 USD
7/15/202619.51 USD
7/14/202619.08 USD
7/13/202618.68 USD
7/10/202620.00 USD
7/9/202620.75 USD
7/8/202619.94 USD
7/7/202619.74 USD
7/6/202619.00 USD
7/2/202618.65 USD
7/1/202617.76 USD
6/30/202618.71 USD
6/29/202619.70 USD
6/26/202618.56 USD
6/25/202617.83 USD
6/24/202618.02 USD
6/23/202617.44 USD
6/22/202616.70 USD
6/18/202616.05 USD
6/17/202615.81 USD
6/16/202614.84 USD
6/15/202615.30 USD
6/12/202614.86 USD
6/11/202614.09 USD
6/10/202614.40 USD
6/9/202614.09 USD
6/8/202613.66 USD
6/5/202613.22 USD
6/4/202614.85 USD
6/3/202615.48 USD
6/2/202616.40 USD
6/1/202613.49 USD
5/29/202614.22 USD
5/28/202614.21 USD
5/27/202614.50 USD
5/26/202613.77 USD
5/22/202613.52 USD
5/21/202614.27 USD
5/20/202612.89 USD
5/19/202612.07 USD
5/18/202612.10 USD
5/15/202612.20 USD
5/14/202612.78 USD
5/13/202613.22 USD
5/12/202612.93 USD
5/11/202612.85 USD
5/8/202612.76 USD
5/7/202612.51 USD
5/6/202612.92 USD
5/5/202613.00 USD
5/4/202613.09 USD
5/1/202612.72 USD
4/30/202612.96 USD
4/29/202612.57 USD
4/28/202613.03 USD
4/27/202614.95 USD
4/24/202615.13 USD
4/23/202615.09 USD
4/22/202616.51 USD
4/21/202616.80 USD
4/20/202616.40 USD
4/17/202616.76 USD
4/16/202616.11 USD
4/15/202615.49 USD
4/14/202614.75 USD
4/13/202615.26 USD
4/10/202614.94 USD
4/9/202615.00 USD
4/8/202614.51 USD
4/7/202613.48 USD
4/6/202612.45 USD
4/2/202612.54 USD
4/1/202610.77 USD
3/31/20269.95 USD
3/30/20269.35 USD
3/27/20269.60 USD
3/26/202610.12 USD
3/25/20269.60 USD
3/24/20269.44 USD
3/23/20269.82 USD
3/20/20269.91 USD
3/19/202610.00 USD
3/18/20269.93 USD
3/17/202610.26 USD
3/16/202610.13 USD
3/13/202610.36 USD
3/12/202610.55 USD
3/11/202610.80 USD
3/10/202610.69 USD
3/9/202610.14 USD
3/6/20269.89 USD
3/5/20269.64 USD
3/4/202610.15 USD
3/3/20269.85 USD
3/2/20269.79 USD
2/27/202610.26 USD
2/26/20269.16 USD
2/25/20269.22 USD
2/24/20269.18 USD
2/23/20268.94 USD
2/20/20268.70 USD
2/19/20268.86 USD
2/18/20269.10 USD
2/17/20269.16 USD
2/13/20268.93 USD
2/12/20268.81 USD
2/11/20269.15 USD
2/10/20268.99 USD
2/9/20268.65 USD
2/6/20268.92 USD
2/5/20268.15 USD
2/4/20268.49 USD
2/3/20268.67 USD
2/2/20268.15 USD
1/30/20267.66 USD
1/29/20267.71 USD
1/28/20267.65 USD
1/27/20268.50 USD
1/26/20267.59 USD
1/23/20267.43 USD
1/22/20267.60 USD
1/21/20267.54 USD
1/20/20267.41 USD
1/16/20267.35 USD
1/15/20267.63 USD
1/14/20268.07 USD
1/13/20267.94 USD
1/12/20267.80 USD
1/9/20267.99 USD
1/8/20268.00 USD
1/7/20268.18 USD
1/6/20268.17 USD
1/5/20267.86 USD
1/2/20268.18 USD
12/31/20258.46 USD
12/30/20258.35 USD
12/29/20258.41 USD
12/26/20258.56 USD
12/24/20258.65 USD
12/23/20258.31 USD
12/22/20258.61 USD
12/19/20258.40 USD
12/18/20258.13 USD
12/17/20258.03 USD
12/16/20258.48 USD
12/15/20258.48 USD
12/12/20258.03 USD
12/11/20257.79 USD
12/10/20257.59 USD
12/9/20257.58 USD
12/8/20257.63 USD
12/5/20257.68 USD
12/4/20258.00 USD
12/3/20257.83 USD
12/2/20257.49 USD
12/1/20257.40 USD
11/28/20257.92 USD
11/26/20258.03 USD
11/25/20258.05 USD
11/24/20258.17 USD
11/21/20256.77 USD
11/20/20256.38 USD
11/19/20256.34 USD
11/18/20256.51 USD
11/17/20256.62 USD
11/14/20256.29 USD
11/13/20256.45 USD
11/12/20256.17 USD
11/11/20256.29 USD
11/10/20256.17 USD
11/7/20256.05 USD
11/6/20256.53 USD
11/5/20256.55 USD
11/4/20256.86 USD
11/3/20256.94 USD
10/31/20257.14 USD
10/30/20257.34 USD
10/29/20257.31 USD
10/28/20257.52 USD
10/27/20257.38 USD
10/24/20256.86 USD
10/23/20256.76 USD
10/22/20256.48 USD
10/21/20257.04 USD
10/20/20257.14 USD
10/17/20256.49 USD
10/16/20256.51 USD
10/15/20256.61 USD
10/14/20256.03 USD
10/13/20256.27 USD
10/10/20256.50 USD
10/9/20256.78 USD
10/8/20256.11 USD
10/7/20255.83 USD
10/6/20255.59 USD
10/3/20255.48 USD
10/2/20255.22 USD
10/1/20255.32 USD
9/30/20255.22 USD
9/29/20255.19 USD
9/26/20255.17 USD
9/25/20254.38 USD
9/24/20254.52 USD
9/23/20254.45 USD
9/22/20254.54 USD
9/19/20254.66 USD
9/18/20254.55 USD
9/17/20254.09 USD
9/16/20254.13 USD
9/15/20254.06 USD
9/12/20253.99 USD
9/11/20254.12 USD
9/10/20254.06 USD
9/9/20254.07 USD
9/8/20254.06 USD
9/5/20254.12 USD
9/4/20254.00 USD
9/3/20254.11 USD
9/2/20253.66 USD
8/29/20253.59 USD
8/28/20253.69 USD
8/27/20253.57 USD
8/26/20253.54 USD
8/25/20253.51 USD
8/22/20253.69 USD
8/21/20253.41 USD
8/20/20253.40 USD
8/19/20253.40 USD
8/18/20253.47 USD
8/15/20253.54 USD
8/14/20253.39 USD
8/13/20253.42 USD
8/12/20253.35 USD
8/11/20253.25 USD
Access this data via the Eulerpool API
Get Free API Key

Relay Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
25.55 M USD
-373.00 M USD
-341.97 M USD
Jan 1, 2024
10.01 M USD
-372.47 M USD
-337.71 M USD
Jan 1, 2025
15.36 M USD
-302.74 M USD
-276.48 M USD
Jan 1, 2026 (e)
11.78 M USD
-11.78 M USD
-221.48 M USD
Jan 1, 2027 (e)
15.99 M USD
-15.99 M USD
-229.08 M USD
Jan 1, 2028 (e)
35.77 M USD
-35.77 M USD
-215.44 M USD
Jan 1, 2029 (e)
183.53 M USD
-183.53 M USD
-143.94 M USD
Jan 1, 2030 (e)
460.42 M USD
-460.42 M USD
-21.63 M USD

Relay Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 10, 2026, 3:39 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201820192020202120222023202420252026e2027e2028e2029e2030e
––82.003.001.0025.0010.0015.0011.0015.0035.00183.00460.00
–––-96.34-66.672,400.00-60.0050.00-26.6736.36133.33422.86151.37
––96.34-5,533.33-24,100.00-1,200.00-3,050.0073.3373.3373.3373.3373.3373.33
-2.00-2.0079.00-166.00-241.00-300.00-305.0011.008.0711.0025.67134.20337.33
-49.00-84.00-55.00-364.00-299.00-373.00-372.00-302.00-11.00-15.00-35.00-183.00-460.00
––-67.07-12,133.33-29,900.00-1,492.00-3,720.00-2,013.33-100.00-100.00-100.00-100.00-100.00
-48.00-66.00-52.00-363.00-290.00-341.00-337.00-276.00-221.00-229.00-215.00-143.00-21.00
–37.50-21.21598.08-20.1117.59-1.17-18.10-19.933.62-6.11-33.49-85.31
171.593.8390.18102.75120.97122.58167.34171.59171.59171.59171.59171.59171.59
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Relay Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Relay Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Relay Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Relay Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Relay Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Relay Therapeutics stock margins

The Relay Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Relay Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Relay Therapeutics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
-5,492.21 %
-12,040.21 %
-12,012.94 %
Jan 1, 2022
-17,496.31 %
-21,670.89 %
-21,036.13 %
Jan 1, 2023
-1,177.64 %
-1,460.11 %
-1,338.66 %
Jan 1, 2024
-3,052.20 %
-3,722.07 %
-3,374.72 %
Jan 1, 2025
76.83 %
-1,971.59 %
-1,800.58 %
Jan 1, 2026 (e)
76.83 %
-100.00 %
-1,880.65 %
Jan 1, 2027 (e)
76.83 %
-100.00 %
-1,432.64 %
Jan 1, 2028 (e)
76.83 %
-100.00 %
-602.26 %

Relay Therapeutics Stock Revenue, EBIT, Earnings per Share

The Relay Therapeutics earnings per share therefore indicates how much revenue Relay Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.03 USD
-3.55 USD
-3.54 USD
Jan 1, 2022
0.01 USD
-2.47 USD
-2.40 USD
Jan 1, 2023
0.21 USD
-3.04 USD
-2.79 USD
Jan 1, 2024
0.06 USD
-2.23 USD
-2.02 USD
Jan 1, 2025
0.09 USD
-1.76 USD
-1.61 USD
Jan 1, 2026 (e)
0.08 USD
-0.07 USD
-1.55 USD
Jan 1, 2027 (e)
0.11 USD
-0.09 USD
-1.60 USD
Jan 1, 2028 (e)
0.25 USD
-0.21 USD
-1.51 USD

Relay Therapeutics business model & stock analysis

Relay Therapeutics Inc - Pioneer in the field of protein therapeutics.

Relay Therapeutics SWOT Analysis

Strengths

Cutting-edge Technology: Relay Therapeutics Inc harnesses advanced technologies in structural biology and machine learning algorithms to drive drug discovery and development.

Experienced Leadership Team: The company benefits from a team of highly skilled professionals with extensive experience in pharmaceuticals, biotechnology, and computational biology, fostering innovation and strategic decision-making.

Strong Intellectual Property Portfolio: Relay Therapeutics possesses a robust portfolio of patents and proprietary technologies, providing a competitive advantage in the industry and protecting its innovations.

Weaknesses

Limited Track Record: As a relatively new company, Relay Therapeutics lacks an extensive track record of successfully bringing drugs to market, making it less attractive to risk-averse investors.

Dependence on Research and Development: The success of Relay Therapeutics heavily depends on its ability to continuously innovate and develop new drugs, thereby requiring substantial investments in research and development.

Opportunities

Expanding Market for Precision Medicines: The increasing demand for more targeted and personalized treatments opens up opportunities for Relay Therapeutics to develop novel therapies tailored to specific diseases and patient populations.

Strategic Collaborations: Forming strategic partnerships and collaborations with established pharmaceutical companies or research institutions can enhance Relay Therapeutics' capabilities, resources, and market reach.

Threats

Intense Competition: The biopharmaceutical industry is highly competitive, with numerous companies vying to develop breakthrough therapies. Relay Therapeutics faces the risk of competitors outperforming or replicating its advancements.

Regulatory Challenges: Adhering to a complex regulatory landscape surrounding drug development and testing poses potential obstacles and delays in obtaining necessary approvals for Relay Therapeutics' products.

Market Volatility: The biotech industry is subject to market volatility and fluctuations, which can impact funding availability, investor confidence, and overall business stability for Relay Therapeutics.

Relay Therapeutics Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Relay Therapeutics Employees
Details
Date
Relay Therapeutics Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Relay Therapeutics Segments

Relay Therapeutics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Relay Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Relay Therapeutics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Relay Therapeutics shares outstanding

The number of shares of Relay Therapeutics was 171.59 M in 2025. This indicates how many shares Relay Therapeutics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
102.75 M Stocks
Jan 1, 2022
120.97 M Stocks
Jan 1, 2023
122.58 M Stocks
Jan 1, 2024
167.34 M Stocks
Jan 1, 2025
171.59 M Stocks
Jan 1, 2026 (e)
171.59 M Stocks
Jan 1, 2027 (e)
171.59 M Stocks
Jan 1, 2028 (e)
171.59 M Stocks

Current Relay Therapeutics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
3.45 %
Buy
94.44 % (17)
Hold
5.56 % (1)
Sell
0.00 % (0)
12M Price Target
14.28
Last Price
19.77
Currency
USD
12M Return Potential
-27.77 %
LTM Return
0 %

Relay Therapeutics Analyst Rating Actions

DateFirmActionRatingReliability
7/21/2026
Goldman Sachs
Goldman Sachs
MaintainedBuy–
5/26/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
5/26/2026
Guggenheim
Guggenheim
MaintainedBuy30
5/20/2026
Citizens
Citizens
MaintainedMarket Outperform–
5/20/2026
Barclays
Barclays
MaintainedOverweight33
5/19/2026
Raymond James
Raymond James
MaintainedStrong Buy74
4/29/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
4/28/2026
Wells Fargo
Wells Fargo
MaintainedOverweight56
4/28/2026
Oppenheimer
Oppenheimer
MaintainedOutperform65
4/28/2026
Goldman Sachs
Goldman Sachs
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Relay Therapeutics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/6/2026-0.40USD-890,184.00USD-2026 Q2
4/30/2026-0.39USD-524,575.00USD-2026 Q1
2/26/2026-0.41USD-5.06 MUSD-2025 Q4
8/7/2025-0.50USD-61,200.00USD-2025 Q2
5/2/2024-0.80USD-40,800.00USD-2024 Q1
2/21/2024-0.78USD-129,815.00USD-2023 Q4
8/2/2023-0.80USD-135,329.00USD-2023 Q2
5/3/2023-0.76USD-135,329.00USD-2023 Q1
2/22/2023-0.71USD-3.35 MUSD-2022 Q4
11/3/2022-0.72USD-1.68 MUSD-2022 Q3

EESG©

Eulerpool ESG Scorecard© for the Relay Therapeutics stock

64/100
35
Environment
99
Social
57
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees46
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Relay Therapeutics shareholder structure

% Name
19.53202%
SB INVESTMENT ADVISERS (UK) LTD
SB INVESTMENT ADVISERS (UK) LTD
11.89911%
COMMODORE CAPITAL LP
COMMODORE CAPITAL LP
10.09225%
CASDIN CAPITAL, LLC
CASDIN CAPITAL, LLC
9.08203%
BLACKROCK, INC.
BLACKROCK, INC.
6.82529%
PERCEPTIVE ADVISORS LLC
PERCEPTIVE ADVISORS LLC
5.45626%
BELLEVUE GROUP AG
BELLEVUE GROUP AG
...

Relay Therapeutics Beneficial Ownership Filings (SEC 13D/G)

Free Float
77.8%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
31.00%
SVF Pauling (Cayman) Limited
SVF Pauling (Cayman) Limited
SEC ↗
31.00%
SoftBank Vision Fund (AIV M2) L.P.
SoftBank Vision Fund (AIV M2) L.P.
SEC ↗
31.00%
SB Investment Advisers (UK) Limited
SB Investment Advisers (UK) Limited
SEC ↗
9.99%
Perceptive Advisors LLC
Perceptive Advisors LLC
SEC ↗
9.95%
FMR LLC
FMR LLC
SEC ↗
9.90%
Commodore Capital LP
Commodore Capital LP
SEC ↗
7.50%
CASDIN CAPITAL, LLC
CASDIN CAPITAL, LLC
SEC ↗
6.10%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
5.74%
The Vanguard Group - 23-1945930
The Vanguard Group - 23-1945930
SEC ↗
5.50%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗

Relay Therapeutics Executives and Management Board

11 members · avg. age 53 · 18 % women

SP

Dr. Sanjiv Patel (51)

President, Chief Executive Officer, Director · since 2017

13.08 M USD

Management

DB

Dr. Donald Bergstrom (53)

President - Research and Development

6.61 M USD
PR

Mr. Peter Rahmer (43)

Chief Corporate Development Officer

4.96 M USD
TC

Mr. Thomas Catinazzo (48)

Chief Financial Officer

4.40 M USD
BA

Mr. Brian Adams (51)

Chief Legal Officer, Secretary

4.37 M USD

Board of Directors

AB

Mr. Alexis Borisy (53)

Independent Chairman of the Board · since 2015

581,136.00 USD
LH

Dr. Linda Hill (68)

Independent Director

551,136.00 USD
DI

Mr. Douglas Ingram (62)

Independent Director

548,636.00 USD
MM

Dr. Mark Murcko (65)

Independent Director · since 2016

548,636.00 USD
SK

Dr. Sekar Kathiresan (53)

Independent Director

538,636.00 USD
CM

Dr. Claire Mazumdar (35)

Independent Director

–

Relay Therapeutics Supply Chain

Relay Therapeutics Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
2 companies
#NameTrend
1
Roche Holding
Supplier·Customer·Pharmaceuticals·CH
0.72
0.87
0.06
0.15
-0.22
—
2
EQRx
Supplier·Customer·Biotechnology·US
-0.01
0.68
0.25
0.45
0.77
—

Frequently asked questions about Relay Therapeutics

Relay Therapeutics Inc's business model focuses on leveraging advanced technologies to transform drug discovery and development. As a biotechnology company, Relay Therapeutics employs an innovative approach that combines computational techniques, biophysical insights, and deep experience in structural biology to design and develop potential therapeutics. By constructing accurate 3D models of proteins, Relay Therapeutics aims to uncover critical information about their function and dysfunction, driving the discovery of novel medicines. The company's business model revolves around applying this cutting-edge platform to identify and advance promising drug candidates, with a particular emphasis on targeted protein degradation and allosteric modulation. Relay Therapeutics Inc strives to address unmet medical needs and improve patient outcomes through its unique, technology-driven approach in drug discovery.

Relay Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Relay Therapeutics Inc in the market include companies such as Vertex Pharmaceuticals, Inc., Beam Therapeutics Inc., and Nurix Therapeutics Inc.

Relay Therapeutics Inc. is a biotechnology company that focuses on discovering and developing new medicines to potentially treat cancer and other diseases. Founded in 2016, Relay Therapeutics combines the fields of computation and experimental biology to design innovative therapies. The company's platform integrates advanced technology, including artificial intelligence and machine learning, to gain a deeper understanding of protein motion and its role in diseases. By leveraging this expertise, Relay Therapeutics aims to discover drugs that can effectively target specific proteins and improve patient outcomes. With its commitment to scientific excellence and cutting-edge research, Relay Therapeutics is dedicated to revolutionizing the field of drug discovery.

Relay Therapeutics Inc has achieved several significant milestones since its inception. This biotechnology company has successfully built a proprietary drug discovery platform that combines computation and experimental approaches to design new small molecule therapies. In 2020, Relay Therapeutics raised approximately $400 million in its initial public offering (IPO), indicating strong market interest in its innovative capabilities. Furthermore, the company has established strategic collaborations with renowned organizations like Genentech and Eli Lilly to accelerate the development of potential breakthrough medicines. These achievements highlight Relay Therapeutics Inc's commitment to revolutionize drug discovery through its cutting-edge platform and strategic partnerships.

Relay Therapeutics Inc is primarily present in the United States.

Relay Therapeutics Inc represents the values of innovation, collaboration, and patient-centricity. The company's corporate philosophy is centered around leveraging the power of protein motion to discover new medicines for patients. Relay Therapeutics is committed to fostering a culture of inclusivity and diversity, empowering its employees to think creatively and work collaboratively towards its mission. By combining cutting-edge technology and deep expertise in structural biology, the company strives to unlock novel insights into protein motion and develop transformative therapies. Relay Therapeutics Inc is dedicated to improving the lives of patients by translating scientific discoveries into impactful medicines.

Analysts currently set an average price target of 14.84 USD for the Relay Therapeutics stock (median: 14.28 USD), implying -25.0 % versus the latest price. The consensus is based on 18 analyst ratings.

Relay Therapeutics Analyst Price Targets 2026

18 analysts currently rate the Relay Therapeutics stock: 17 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Relay Therapeutics to generate revenue of 11.78 M USD and earnings per share of -1.29 USD.

Relay Therapeutics Analyst Price Targets 2026

Converted at the current exchange rate, the Relay Therapeutics share trades at 17.11 EUR (19.77 USD).

The Relay Therapeutics share (RLAY) is listed on 1 stock exchanges, including: NASDAQ (RLAY).

Relay Therapeutics is an innovative biotechnology company focused on the discovery and development of new drugs for serious diseases. The company was founded in 2016 and uses a unique computer-based approach to identify new targets for drugs. The company concentrates on developing drugs for diseases that currently lack effective treatments. It employs a computer-based approach to identify new targets for drugs. Relay Therapeutics has developed an innovative technology platform that combines synthetic chemistry and modern biology. Relay Therapeutics offers a wide range of products and services to its customers. The company utilizes a dynamic and customer-centric business strategy, ensuring that it meets the needs of its customers while remaining innovative. Collaborating with other companies and institutions to leverage its technology and expertise and develop innovative products and services is a crucial component of Relay Therapeutics' business model. The company partners with other companies and universities to develop innovative drugs and diagnostic procedures. Relay Therapeutics has already established successful partnerships with major pharmaceutical companies such as Sanofi and Vertex Pharmaceuticals, as well as other industry leaders. Relay Therapeutics has built a strong pipeline of projects focusing on the development of new drugs. Its research programs concentrate on developing drugs for cancer, neurodegenerative diseases, and rare diseases. Furthermore, Relay Therapeutics also relies on strategic partnerships to expand its product pipeline and enter new markets. The company has already established successful partnerships with major pharmaceutical companies such as Sanofi and Vertex Pharmaceuticals, as well as other industry leaders. The business model of Relay Therapeutics is based on the following key components: - Utilization of technology platforms: Relay Therapeutics utilizes state-of-the-art computer-based technology platforms to identify new targets for drugs. - Focus on serious diseases: Relay Therapeutics focuses on developing drugs for serious diseases that currently lack effective treatments. - Collaboration with other companies and institutions: Relay Therapeutics collaborates with other companies and institutions to leverage its technology and expertise in developing innovative products and services together. - Wide range of products and services: Relay Therapeutics offers a wide range of products and services tailored to the needs of its customers. Overall, Relay Therapeutics employs a collaborative business strategy to develop innovative drugs for serious diseases. With its technology platforms, research programs, and strategic partnerships, the company has gained a strong position in the biotechnology industry and is well-positioned to continue developing innovative solutions for the healthcare sector.

The expected revenue of Relay Therapeutics is 11.78 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Relay Therapeutics is -221.48 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Relay Therapeutics is currently -15.32. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Relay Therapeutics stock.

The price-to-sales ratio (P/S) of Relay Therapeutics is currently 288.04. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Relay Therapeutics stock.

The Eulerpool Quality Score for Relay Therapeutics is 3/10.

The ISIN of Relay Therapeutics is US75943R1023. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Relay Therapeutics is A2P9AA. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Relay Therapeutics is RLAY. The ticker symbol is used to trade Relay Therapeutics shares on the stock exchange.

Relay Therapeutics paid dividends every year for the past 0 years.

Relay Therapeutics is assigned to the 'Health' sector.

The dividends of Relay Therapeutics are distributed in USD.

All fundamentals and in-depth analysis of Relay Therapeutics

Our stock analysis for Relay Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Relay Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Relay Therapeutics Stock
Relay Therapeutics Revenue→
Relay Therapeutics Stock
Relay Therapeutics Net Income→
Relay Therapeutics Stock
Relay Therapeutics P/E→
Relay Therapeutics Stock
Relay Therapeutics P/S→
Relay Therapeutics Stock
Relay Therapeutics EBIT→
Relay Therapeutics Stock
Relay Therapeutics Dividend→
Relay Therapeutics Stock
Relay Therapeutics Directors Dealings→
Relay Therapeutics Stock
Relay Therapeutics Stocks→
Relay Therapeutics Stock
Relay Therapeutics Market capitalization→
Relay Therapeutics Stock
Relay Therapeutics Debt→
Relay Therapeutics Stock
Relay Therapeutics Liabilities→
Relay Therapeutics Stock
Relay Therapeutics Equity→
Relay Therapeutics Stock
Relay Therapeutics AAQS→
Relay Therapeutics Stock
Relay Therapeutics Employees→
Relay Therapeutics Stock
Relay Therapeutics ROE→
Relay Therapeutics Stock
Relay Therapeutics ROA→
Relay Therapeutics Stock
Relay Therapeutics ROCE→
Relay Therapeutics Stock
Relay Therapeutics News→
Relay Therapeutics Stock
Relay Therapeutics Analyst Price Targets→

Health Stocks

Relmada TherapeuticsRekah Pharmaceutical IndustryRemed CoRein TherapeuticsRemedentRegis HealthcareRemeGen CoRegenxbioRemeGen CoRegeneRx BiopharmaceuticalsREMSleep HoldingsRegeneron PharmaceuticalsAll Stocks A–Z →